Isoxyl is a potent antituberculosis drug effective in treating various multidrug-resistant strains of Mycobacterium without any known side effect. It has been used exclusively and infrequently via oral route. As it is sparingly soluble in water, it exhibited very poor and highly variable bioavailability due to which the use of this drug is abandoned. Delivery of isoxyl to the lungs, a major site of Mycobacterium tuberculosis infection, is an attractive alternative route of administration that may rescue this abandoned drug for a disease that urgently requires new therapies[1].
Pharmacokinetics and tissues distribution of ethionamide encapsulated in poly (DL-lactide-co-glycolide) (PLGA) nanoparticles is studied by Kumar et al[2]. Ethionamide-loaded nanoparticles were administered orally to mice at 2 different doses and the control group received free (unencapsulated) ethionamide. Ethionamide-loaded PLGA nanoparticles produced sustained release of ethionamide for 6 days in plasma against 6 h for free ethionamide. The Ethionamide was detected in organs (lung, liver, and spleen) for up to 5-7 days in the case of encapsulated ethionamide, whereas free ethionamide was cleared within 12 h. Ethionamide-loaded PLGA nanoparticles exhibited significant improvement in pharmacokinetic parameters of encapsulated ethionamide as compared with free ethionamide.
A patent application has been filed by Piramal Life Sciences Ltd.[3] wherein a biodegradable, inhalable microparticle formulation comprising a compound obtained by fermentation of a microorganism of the Streptomyces species ( PM 0626271 /MTCC5447), as described in PCT application publication WO2011027290, and a biodegradable lipid for drug delivery has been used. Method of treatment of pulmonary tuberculosis, multi drug resistant tuberculosis (MDRTB), methicillin resistant Staphylococcus aureus (MRSA) pneumonias and methicillin sensitive Staphylococcus aureus (MSSA) pneumonias, by administering therapeutically effective amount of the formulation has been disclosed in the patent application.
Key Words: multidrug resistant tuberculosis, extensively drug resistant tuberculosis, multidrug resistant TB, extensively drug resistant TB, MDR TB, XDR TB, mycobacterium tuberculosis, mycobacterial infection, literature, research, publications, patents.
Key Words: multidrug resistant tuberculosis, extensively drug resistant tuberculosis, multidrug resistant TB, extensively drug resistant TB, MDR TB, XDR TB, mycobacterium tuberculosis, mycobacterial infection, literature, research, publications, patents.
[1] Wang, Chenchen & Hickey, Anthony J. (Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA). AAPS PharmSciTech, 11(2), 538-549 (English) 2010
[2] Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Kumar et al., (Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India). Drug Delivery, 18(1), 65-73 (English) 2011.
[3] MICROPARTICLE FORMULATION FOR PULMONARY DRUG DELIVERY OF ANTI-INFECTIVE MOLECULE FOR TREATMENT OF INFECTIOUS DISEASES. WO2012017405 (A1) ― 2012-02-09.
No comments:
Post a Comment